Genetic Profiling of Human Hepatocellular Carcinoma

ABSTRACT

The underlying molecular basis for the heterogeneity in human liver cancer, hepatocellular carcinoma (HCC), is largely unknown. As with most other human cancers, the heterogeneous nature of HCC has hampered both treatment and prognostic predictions. Global gene expression profiling of human cancers is a promising new technology for refining the diagnosis and prognosis of HCC as well as for identifying potential therapeutic targets. Improved molecular characterization of HCC from gene expression profiling studies will undoubtedly improve the prediction of treatment responses, improve the selection of treatments for specific molecular subtypes of HCC, and ultimately improve the clinical outcome of HCC patients. We review the recent advances in gene expression profiling of HCC and discuss the biological and clinical insights obtained from these studies.

Hepatocellular carcinoma (HCC) - DNA microarray - gene expression profile - comparative functional genomics

REFERENCES

• 1 Bruix J, Boix L, Sala M, Llovet J M. Focus on hepatocellular carcinoma.  Cancer Cell. 2004;  5 215-219
• 2 Llovet J M, Burroughs A, Bruix J. Hepatocellular carcinoma.  Lancet. 2003;  362 1907-1917
• 3 Thorgeirsson S S, Grisham J W. Molecular pathogenesis of human hepatocellular carcinoma.  Nat Genet. 2002;  31 339-346
• 4 Lee J S, Thorgeirsson S S. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets.  Gastroenterology. 2004;  127 S51-S55
• 5 Ramaswamy S. Translating cancer genomics into clinical oncology.  N Engl J Med. 2004;  350 1814-1816
• 6 Alizadeh A A, Eisen M B, Davis R E et al.. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.  Nature. 2000;  403 503-511
• 7 Beer D G, Kardia S L, Huang C C et al.. Gene-expression profiles predict survival of patients with lung adenocarcinoma.  Nat Med. 2002;  8 816-824
• 8 Bittner M, Meltzer P, Chen Y et al.. Molecular classification of cutaneous malignant melanoma by gene expression profiling.  Nature. 2000;  406 536-540
• 9 Roepman P, Wessels L F, Kettelarij N et al.. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas.  Nat Genet. 2005;  37 182-186
• 10 Valk P J, Verhaak R G, Beijen M A et al.. Prognostically useful gene-expression profiles in acute myeloid leukemia.  N Engl J Med. 2004;  350 1617-1628
• 11 van't Veer L J, Dai H, van de Vijver M J et al.. Gene expression profiling predicts clinical outcome of breast cancer.  Nature. 2002;  415 530-536
• 12 Heller M J. DNA microarray technology: devices, systems, and applications.  Annu Rev Biomed Eng. 2002;  4 129-153 , Epub; 2002 Mar 22:129-153
• 13 Liang P, Pardee A B. Analysing differential gene expression in cancer.  Nat Rev Cancer. 2003;  3 869-876
• 14 Liang P, Pardee A B. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction.  Science. 1992;  257 967-971
• 15 Diatchenko L, Lau Y F, Campbell A P et al.. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries.  Proc Natl Acad Sci USA. 1996;  93 6025-6030
• 16 Lisitsyn N, Lisitsyn N, Wigler M. Cloning the differences between two complex genomes.  Science. 1993;  259 946-951
• 17 Velculescu V E, Zhang L, Vogelstein B, Kinzler K W. Serial analysis of gene expression.  Science. 1995;  270 484-487
• 18 Schena M, Shalon D, Davis R W, Brown P O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray.  Science. 1995;  270 467-470
• 19 Brenner S, Johnson M, Bridgham J et al.. Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays.  Nat Biotechnol. 2000;  18 630-634
• 20 Bruix J, Llovet J M. HCC surveillance: who is the target population?.  Hepatology. 2003;  37 507-509
• 21 Calvet X, Bruix J, Gines P et al.. Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients.  Hepatology. 1990;  12 753-760
• 22 Chevret S, Trinchet J C, Mathieu D et al.. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire.  J Hepatol. 1999;  31 133-141
• 23 Okuda K, Ohtsuki T, Obata H et al.. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients.  Cancer. 1985;  56 918-928
• 24 Pugh R N, Murray-Lyon I M, Dawson J L et al.. Transection of the oesophagus for bleeding oesophageal varices.  Br J Surg. 1973;  60 646-649
• 25 Tan C K, Law N M, Ng H S, Machin D. Simple clinical prognostic model for hepatocellular carcinoma in developing countries and its validation.  J Clin Oncol. 2003;  21 2294-2298
• 26 CLIP investigators . A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators.  Hepatology. 1998;  28 751-755
• 27 Chen X, Cheung S T, So S et al.. Gene expression patterns in human liver cancers.  Mol Biol Cell. 2002;  13 1929-1939
• 28 Kim B Y, Lee J G, Park S et al.. Feature genes of hepatitis B virus-positive hepatocellular carcinoma, established by its molecular discrimination approach using prediction analysis of microarray.  Biochim Biophys Acta. 2004;  1739 50-61
• 29 Neo S Y, Leow C K, Vega V B et al.. Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach.  Hepatology. 2004;  39 944-953
• 30 Xu X R, Huang J, Xu Z G et al.. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver.  Proc Natl Acad Sci USA. 2001;  98 15089-15094
• 31 Anders R A, Yerian L M, Tretiakova M et al.. cDNA microarray analysis of macroregenerative and dysplastic nodules in end-stage hepatitis C virus-induced cirrhosis.  Am J Pathol. 2003;  162 991-1000
• 32 Delpuech O, Trabut J B, Carnot F et al.. Identification, using cDNA macroarray analysis, of distinct gene expression profiles associated with pathological and virological features of hepatocellular carcinoma.  Oncogene. 2002;  21 2926-2937
• 33 Iizuka N, Oka M, Yamada-Okabe H et al.. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection.  Lancet. 2003;  361 923-929
• 34 Lee J S, Thorgeirsson S S. Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer.  Hepatology. 2002;  35 1134-1143
• 35 Okabe H, Satoh S, Kato T et al.. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression.  Cancer Res. 2001;  61 2129-2137
• 36 Paradis V, Bieche I, Dargere D et al.. Molecular profiling of hepatocellular carcinomas (HCC) using a large-scale real-time RT-PCR approach: determination of a molecular diagnostic index.  Am J Pathol. 2003;  163 733-741
• 37 Smith M W, Yue Z N, Korth M J et al.. Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers.  Hepatology. 2003;  38 1458-1467
• 38 Smith M W, Yue Z N, Geiss G K et al.. Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma.  Cancer Res. 2003;  63 859-864
• 39 Ye Q H, Qin L X, Forgues M et al.. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning.  Nat Med. 2003;  9 416-423
• 40 Lee J S, Chu I S, Heo J et al.. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling.  Hepatology. 2004;  40 667-676
• 41 Van Dyke T, Jacks T. Cancer modeling in the modern era: progress and challenges.  Cell. 2002;  108 135-144
• 42 Klausner R D. Studying cancer in the mouse.  Oncogene. 1999;  18 5249-5252
• 43 Ellwood-Yen K, Graeber T G, Wongvipat J et al.. Myc-driven murine prostate cancer shares molecular features with human prostate tumors.  Cancer Cell. 2003;  4 223-238
• 44 Lee J S, Chu I S, Mikaelyan A et al.. Application of comparative functional genomics to identify best-fit mouse models to study human cancer.  Nat Genet. 2004;  36 1306-1311
• 45 Sweet-Cordero A, Mukherjee S, Subramanian A et al.. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis.  Nat Genet. 2005;  37 48-55
• 46 Wistuba I I, Gazdar A F, Minna J D. Molecular genetics of small cell lung carcinoma.  Semin Oncol. 2001;  28 3-13
• 47 Beer D G, Kardia S L, Huang C C et al.. Gene-expression profiles predict survival of patients with lung adenocarcinoma.  Nat Med. 2002;  8 816-824
• 48 Fan C Y, Pan J, Usuda N et al.. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism.  J Biol Chem. 1998;  273 15639-15645
• 49 Rao M S, Lalwani N D, Watanabe T K, Reddy J K. Inhibitory effect of antioxidants ethoxyquin and 2(3)-tert-butyl-4-hydroxyanisole on hepatic tumorigenesis in rats fed ciprofibrate, a peroxisome proliferator.  Cancer Res. 1984;  44 1072-1076
• 50 Reddy J K, Lalwai N D. Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans.  Crit Rev Toxicol. 1983;  12 1-58
• 51 Gonzalez F J, Peters J M, Cattley R C. Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha.  J Natl Cancer Inst. 1998;  90 1702-1709
• 52 Calvisi D F, Factor V M, Ladu S, Conner E A, Thorgeirsson S S. Disruption of β-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice.  Gastroenterology. 2004;  126 1374-1386
• 53 Sargent L M, Zhou X, Keck C L et al.. Nonrandom cytogenetic alterations in hepatocellular carcinoma from transgenic mice overexpressing c-Myc and transforming growth factor-alpha in the liver.  Am J Pathol. 1999;  154 1047-1055
• 54 Calvisi D F, Factor V M, Loi R, Thorgeirsson S S. Activation of β-catenin during hepatocarcinogenesis in transgenic mouse models: relationship to phenotype and tumor grade.  Cancer Res. 2001;  61 2085-2091
• 55 Hsu H C, Jeng Y M, Mao T L et al.. β-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis.  Am J Pathol. 2000;  157 763-770
• 56 Mao T L, Chu J S, Jeng Y M et al.. Expression of mutant nuclear β-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis.  J Pathol. 2001;  193 95-101
• 57 Wong C M, Fan S T, Ng I O. β-catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance.  Cancer. 2001;  92 136-145
• 58 Laurent-Puig P, Legoix P, Bluteau O et al.. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis.  Gastroenterology. 2001;  120 1763-1773
• 59 Yarden Y, Sliwkowski M X. Untangling the ErbB signalling network.  Nat Rev Mol Cell Biol. 2001;  2 127-137
• 60 Cohen M H, Williams G A, Sridhara R et al.. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839, Iressa) tablets.  Clin Cancer Res. 2004;  10 1212-1218
• 61 Kitano H. Cancer robustness: tumour tactics.  Nature. 2003;  426 125
• 62 McNeil C. Herceptin raises its sights beyond advanced breast cancer.  J Natl Cancer Inst. 1998;  90 882-883
• 63 le Coutre P, Mologni L, Cleris L et al.. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.  J Natl Cancer Inst. 1999;  91 163-168
• 64 Paez J G, Janne P A, Lee J C et al.. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.  Science. 2004;  304 1497-1500
• 65 Lynch T J, Bell D W, Sordella R et al.. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.  N Engl J Med. 2004;  350 2129-2139